154 related articles for article (PubMed ID: 28938378)
1. Severe Corneal Disorders Developed After Brimonidine Tartrate Ophthalmic Solution Use.
Maruyama Y; Ikeda Y; Yokoi N; Mori K; Kato H; Ueno M; Kinoshita S; Sotozono C
Cornea; 2017 Dec; 36(12):1567-1569. PubMed ID: 28938378
[TBL] [Abstract][Full Text] [Related]
2. Corneal sterile infiltration induced by topical use of ocular hypotensive agent.
Manabe Y; Sawada A; Mochizuki K
Eur J Ophthalmol; 2020 Sep; 30(5):NP23-NP25. PubMed ID: 31096781
[TBL] [Abstract][Full Text] [Related]
3. A case of bilateral deep stromal corneal opacity and vascularization after use of multiple antiglaucoma medications including brimonidine tartrate ophthalmic solution.
Tsujinaka A; Takai Y; Inoue Y; Tanito M
Acta Ophthalmol; 2019 Sep; 97(6):e948-e949. PubMed ID: 30609169
[No Abstract] [Full Text] [Related]
4. Corneal Opacity Induced by Antiglaucoma Agents Other Than Brimonidine Tartrate.
Kasuya Y; Sano I; Makino S; Kawashima H
Case Rep Ophthalmol Med; 2020; 2020():4803651. PubMed ID: 32547800
[TBL] [Abstract][Full Text] [Related]
5. Brimonidine-timolol fixed combination induced granulomatous inflammation of the eye.
Carrasco MA; Schlaen BA; Zárate JO
Int Ophthalmol; 2013 Oct; 33(5):557-60. PubMed ID: 23224363
[TBL] [Abstract][Full Text] [Related]
6. Demographic and clinical factors associated with development of brimonidine tartrate 0.2%-induced ocular allergy.
Manni G; Centofanti M; Sacchetti M; Oddone F; Bonini S; Parravano M; Bucci MG
J Glaucoma; 2004 Apr; 13(2):163-7. PubMed ID: 15097264
[TBL] [Abstract][Full Text] [Related]
7. Inflammatory Cells and Lipid Deposits Detected by
Chikama T; Shinji K; Yokota C; Hayashi K; Kiuchi Y
Ocul Immunol Inflamm; 2023 Nov; 31(9):1842-1847. PubMed ID: 36306423
[TBL] [Abstract][Full Text] [Related]
8. Interstitial Keratitis with Lipid Keratopathy Mimicking Corneal Opacity Induced by Brimonidine Tartrate Eye Drops.
Kasuya Y; Sano I; Makino S
Klin Monbl Augenheilkd; 2020 Dec; 237(12):1466-1467. PubMed ID: 33285590
[No Abstract] [Full Text] [Related]
9. Brimonidine related acute follicular conjunctivitis: Onset time and clinical presentations, a long-term follow-up.
Yeh PH; Cheng YC; Shie SS; Lee YS; Shen SC; Chen HS; Wu WC; Su WW
Medicine (Baltimore); 2021 Jul; 100(29):e26724. PubMed ID: 34398046
[TBL] [Abstract][Full Text] [Related]
10. Brimonidine-induced unilateral ocular lichen planus: a case report.
Ventura-Abreu N; Fernández-Aceñero MJ; Narváez-Palazón C; Romo-López A
Arq Bras Oftalmol; 2019; 82(3):236-238. PubMed ID: 30916215
[TBL] [Abstract][Full Text] [Related]
11. Allergic contact dermatitis probably due to brimonidine tartrate in eyedrops.
Napolitano M; Potestio L; Castagliola C; Fabbrocini G; Patruno C
Contact Dermatitis; 2021 Sep; 85(3):382-384. PubMed ID: 33861874
[No Abstract] [Full Text] [Related]
12. Brimonidine and brinzolamide for treating glaucoma and ocular hypertension; a safety evaluation.
Lusthaus JA; Goldberg I
Expert Opin Drug Saf; 2017 Sep; 16(9):1071-1078. PubMed ID: 28656780
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo corneal effects of latanoprost combined with brimonidine, timolol, dorzolamide, or brinzolamide.
Fukuda M; Takeda N; Shibata S; Shibata N; Shibata T; Sugiyama K; Sasaki H
Eur J Pharmacol; 2016 Sep; 787():43-6. PubMed ID: 27181069
[TBL] [Abstract][Full Text] [Related]
14. Reversible cicatricial ectropion precipitated by topical brimonidine eye drops.
Aristodemou P; Baer R
Ophthalmic Plast Reconstr Surg; 2008; 24(1):57-8. PubMed ID: 18209648
[TBL] [Abstract][Full Text] [Related]
15. A Case of Sterile Corneal Stromal Infiltration with Hypotonic Maculopathy Under Brimonidine Treatment.
Vidal Oliver L; Díaz Barrón A; López Montero A; Gil-Hernández I; Duch Samper AM
Ocul Immunol Inflamm; 2023 Oct; 31(8):1716-1719. PubMed ID: 35708458
[TBL] [Abstract][Full Text] [Related]
16. High Permeability and Intercellular Space Widening With Brimonidine Tartrate Eye Drops in Cultured Stratified Human Corneal Epithelial Sheets.
Hashimoto Y; Yokoo S; Usui T; Tsubota Y; Yamagami S
Cornea; 2018 Feb; 37(2):242-247. PubMed ID: 29135708
[TBL] [Abstract][Full Text] [Related]
17. The chemotactic properties of various topical brimonidine tartrate ophthalmic preparations.
Alonso RS; Solari HP; de França Damasceno E; Burnier MNN; Ventura MP
BMC Pharmacol Toxicol; 2020 Mar; 21(1):24. PubMed ID: 32293549
[TBL] [Abstract][Full Text] [Related]
18. A review of neuropsychiatric adverse events from topical ophthalmic brimonidine.
Cimolai N
Hum Exp Toxicol; 2020 Oct; 39(10):1279-1290. PubMed ID: 32347114
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the intraocular pressure-lowering effect and safety of brimonidine/timolol fixed combination and 0.5% timolol in normal-tension glaucoma patients.
Kim JM; Kim TW; Kim CY; Kim HK; Park KH
Jpn J Ophthalmol; 2016 Jan; 60(1):20-6. PubMed ID: 26578422
[TBL] [Abstract][Full Text] [Related]
20. GS-101 antisense oligonucleotide eye drops inhibit corneal neovascularization: interim results of a randomized phase II trial.
Cursiefen C; Bock F; Horn FK; Kruse FE; Seitz B; Borderie V; Früh B; Thiel MA; Wilhelm F; Geudelin B; Descohand I; Steuhl KP; Hahn A; Meller D
Ophthalmology; 2009 Sep; 116(9):1630-7. PubMed ID: 19643487
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
